| Product Code: ETC12629538 | Publication Date: Apr 2025 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
In 2024, Finland saw significant import shipments of large molecules drug substances from top countries including the USA, Germany, UK, Austria, and New Zealand. The high Herfindahl-Hirschman Index (HHI) indicates a concentrated market, while the impressive compound annual growth rate (CAGR) of 24.17% from 2020 to 2024 highlights a thriving industry. However, the negative growth rate of -20.18% in 2024 suggests a temporary setback that may require further analysis to understand the market dynamics.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Finland Large Molecules Drug Substance CDMO Market Overview |
3.1 Finland Country Macro Economic Indicators |
3.2 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Finland Large Molecules Drug Substance CDMO Market - Industry Life Cycle |
3.4 Finland Large Molecules Drug Substance CDMO Market - Porter's Five Forces |
3.5 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Service Type, 2021 & 2031F |
3.6 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Molecule Type, 2021 & 2031F |
3.7 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Stage, 2021 & 2031F |
3.8 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.9 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Finland Large Molecules Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for large molecule drug development services in Finland |
4.2.2 Growing trend towards outsourcing drug substance manufacturing to CDMOs |
4.2.3 Technological advancements and expertise of CDMOs in handling large molecules |
4.3 Market Restraints |
4.3.1 Regulatory challenges and stringent quality requirements in large molecule drug manufacturing |
4.3.2 Competition from other global CDMOs offering similar services |
5 Finland Large Molecules Drug Substance CDMO Market Trends |
6 Finland Large Molecules Drug Substance CDMO Market, By Types |
6.1 Finland Large Molecules Drug Substance CDMO Market, By Service Type |
6.1.1 Overview and Analysis |
6.1.2 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Service Type, 2021 - 2031F |
6.1.3 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Process Development, 2021 - 2031F |
6.1.4 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Manufacturing, 2021 - 2031F |
6.1.5 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Analytical Services, 2021 - 2031F |
6.1.6 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Regulatory Support, 2021 - 2031F |
6.1.7 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Packaging, 2021 - 2031F |
6.2 Finland Large Molecules Drug Substance CDMO Market, By Molecule Type |
6.2.1 Overview and Analysis |
6.2.2 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Monoclonal Antibodies, 2021 - 2031F |
6.2.3 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Recombinant Proteins, 2021 - 2031F |
6.2.4 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Peptides, 2021 - 2031F |
6.2.5 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Nucleic Acids, 2021 - 2031F |
6.2.6 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Viral Vectors, 2021 - 2031F |
6.3 Finland Large Molecules Drug Substance CDMO Market, By Stage |
6.3.1 Overview and Analysis |
6.3.2 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Preclinical, 2021 - 2031F |
6.3.3 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Clinical, 2021 - 2031F |
6.3.4 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Commercial, 2021 - 2031F |
6.3.5 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Late-Stage, 2021 - 2031F |
6.3.6 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Early-Stage, 2021 - 2031F |
6.4 Finland Large Molecules Drug Substance CDMO Market, By Application |
6.4.1 Overview and Analysis |
6.4.2 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Oncology, 2021 - 2031F |
6.4.3 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Immunology, 2021 - 2031F |
6.4.4 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Neurology, 2021 - 2031F |
6.4.5 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Rare Diseases, 2021 - 2031F |
6.4.6 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Infectious Diseases, 2021 - 2031F |
6.5 Finland Large Molecules Drug Substance CDMO Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Pharmaceutical Companies, 2021 - 2031F |
6.5.3 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Biopharmaceutical Companies, 2021 - 2031F |
6.5.4 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By Research Institutes, 2021 - 2031F |
6.5.5 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By CROs, 2021 - 2031F |
6.5.6 Finland Large Molecules Drug Substance CDMO Market Revenues & Volume, By CMOs, 2021 - 2031F |
7 Finland Large Molecules Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Finland Large Molecules Drug Substance CDMO Market Export to Major Countries |
7.2 Finland Large Molecules Drug Substance CDMO Market Imports from Major Countries |
8 Finland Large Molecules Drug Substance CDMO Market Key Performance Indicators |
8.1 Average project turnaround time for large molecule drug substance manufacturing |
8.2 Percentage of successful technology transfers between clients and CDMOs |
8.3 Number of new partnerships and collaborations formed by CDMOs within the Finnish market |
9 Finland Large Molecules Drug Substance CDMO Market - Opportunity Assessment |
9.1 Finland Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Service Type, 2021 & 2031F |
9.2 Finland Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Molecule Type, 2021 & 2031F |
9.3 Finland Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Stage, 2021 & 2031F |
9.4 Finland Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Application, 2021 & 2031F |
9.5 Finland Large Molecules Drug Substance CDMO Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Finland Large Molecules Drug Substance CDMO Market - Competitive Landscape |
10.1 Finland Large Molecules Drug Substance CDMO Market Revenue Share, By Companies, 2024 |
10.2 Finland Large Molecules Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here